FTSE MIB
33.308,77 -366,33 (-1,09%) Dow Jones
39.150,33 +15,53 (+0,04%) Nasdaq
17.689,36 -32,24 (-0,18%) Nikkei 225
38.596,47 -36,53 (-0,09%) Petrolio
80,59 -0,14 (-0,17%) Bitcoin EUR
59.957,78 -178,33 (-0,30%)
Revance Therapeutics, Inc. (RVNC)
Dopo ore:
Revance Therapeutics, Inc.
1222 Demonbreun Street
Suite 2000
Nashville, TN 37203
United States
615 724 7755
https://www.revance.com
Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 597
Descrizione
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing OnabotulinumtoxinA, a biosimilar to BOTOX that is in preclinical stage. The company also offers Resilient Hyaluronic Acid (RHA) dermal filler for the correction of moderate to severe dynamic facial wrinkles; and RHA Redensity, a dermal filler for the treatment of moderate to severe dynamic perioral rhytids. It has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.
Governance aziendale
L'ISS Governance QualityScore di Revance Therapeutics, Inc. al 1 giugno 2024 è 6. I criteri di valutazione fondamentali sono revisione: 1; Consiglio di Amministrazione: 6; diritti degli azionisti: 7; retribuzione: 8.
